ELBIT MEDICAL IMAGING LTD. ANNOUNCES - INSIGHTEC RECEIVES
EUROPEAN CE MARK FOR EXABLATE® 2000 TREATMENT OF PAIN
CAUSED BY BONE METASTASES
Tel-Aviv, Israel, June 6, 2007 - Elbit Medical Imaging Ltd. (NASDAQ:EMITF)(“EMI”) today announced that, its subsidiary (in which EMI holds indirectly approximately 52%), InSightec Ltd., announced today that its ExAblate® 2000
system has received the CE Mark certification for pain palliation of bone metastases.
Bone is the third most common organ to which cancer metastasizes, after the lungs and liver. Almost all patients with metastatic prostate cancer have skeletal metastases and in breast cancer, bone is the second most common site of metastatic spread,
affecting 90% of patients with progressive breast cancer. It is estimated 100,000 in Europe are diagnosed with bone metastases every year. Most cancer patients suffer from pain; controlling it and managing its symptoms are important treatment goals.
In clinical studies, which supported the CE mark certification, patients reported their pain levels using VAS (Visual Analog Score), a pain questionnaire used to monitor changes in pain levels and assess the efficacy of pain management. The majority of patients reported an immediate improvement in pain scores. Many also reported that they stopped using any analgesic pain relief.
“ExAblate 2000 has been used to successfully treat uterine fibroids non-invasively
with Magnetic Resonance guided Focused Ultrasound (MRgFUS) and this second CE Mark represents a significant milestone in our quest to expand the potential applications of this non-invasive, innovative therapy for oncology applications providing improved care for patients around the world,” said Dr. Kobi Vortman,
President and CEO of InSightec.
“This procedure can alleviate the patient’s pain, has the potential to lower reliance on
analgesics and provide patients with the opportunity for improved quality of life.”
